GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

US-based affordable medicine developer EQRx secured $500m yesterday in a series B round featuring healthcare software producer Nextech and GV, a corporate vehicle for internet and technology group Alphabet. The round included all the participants in the $200m series A round EQRx disclosed when it emerged from stealth in January 2020, including Andreessen Horowitz, Section…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.